BR112022026922A2 - Anticorpo anti-lilrb1 e usos do mesmo - Google Patents
Anticorpo anti-lilrb1 e usos do mesmoInfo
- Publication number
- BR112022026922A2 BR112022026922A2 BR112022026922A BR112022026922A BR112022026922A2 BR 112022026922 A2 BR112022026922 A2 BR 112022026922A2 BR 112022026922 A BR112022026922 A BR 112022026922A BR 112022026922 A BR112022026922 A BR 112022026922A BR 112022026922 A2 BR112022026922 A2 BR 112022026922A2
- Authority
- BR
- Brazil
- Prior art keywords
- lilrb1
- same
- lilrb1 antibody
- antibody
- antigen
- Prior art date
Links
- 102000004569 Leukocyte Immunoglobulin-like Receptor B1 Human genes 0.000 abstract 1
- 108010017736 Leukocyte Immunoglobulin-like Receptor B1 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
ANTICORPO ANTI-LILRB1 E USOS DO MESMO. A presente invenção refere-se a um anticorpo anti-LILRB1 com especificidade aumentada para LILRB1 e a usos do m esmo. Especificamente, um anticorpo anti-LILRB1 ou um fragmento de ligação ao antígeno do mesmo e seus usos no tratamento do câncer são fornecidos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200094053 | 2020-07-28 | ||
| PCT/KR2021/009696 WO2022025585A1 (ko) | 2020-07-28 | 2021-07-27 | 항-lilrb1 항체 및 그의 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022026922A2 true BR112022026922A2 (pt) | 2023-02-07 |
Family
ID=80036572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022026922A BR112022026922A2 (pt) | 2020-07-28 | 2021-07-27 | Anticorpo anti-lilrb1 e usos do mesmo |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230374127A1 (pt) |
| EP (1) | EP4169950A4 (pt) |
| JP (1) | JP2023537225A (pt) |
| KR (1) | KR20220014316A (pt) |
| CN (1) | CN115867353A (pt) |
| AU (1) | AU2021315366A1 (pt) |
| BR (1) | BR112022026922A2 (pt) |
| CA (1) | CA3186256A1 (pt) |
| IL (1) | IL299942A (pt) |
| MX (1) | MX2023001041A (pt) |
| TW (2) | TW202340258A (pt) |
| WO (1) | WO2022025585A1 (pt) |
| ZA (1) | ZA202213434B (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023170434A1 (en) | 2022-03-11 | 2023-09-14 | Macomics Limited | Compositions and methods for modulation of macrophage activity |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101038126B1 (ko) | 2010-11-30 | 2011-05-31 | 주식회사 엘지생명과학 | 새로운 융합 프로모터 및 이를 포함하는 재조합 벡터 |
| WO2013181438A2 (en) * | 2012-05-30 | 2013-12-05 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for modulating pro-inflammatory immune response |
| ES2944982T3 (es) * | 2015-08-05 | 2023-06-27 | Janssen Biotech Inc | Anticuerpos anti-CD154 y métodos para utilizarlos |
| CN109790213B (zh) * | 2016-07-29 | 2022-10-18 | 德克萨斯大学体系董事会 | 用于鉴定lilrb阻断抗体的方法 |
| EP3740224A4 (en) * | 2018-01-18 | 2022-05-04 | Adanate, Inc. | ANTI-LILRB ANTIBODIES AND THEIR USES |
| CA3120476A1 (en) * | 2018-12-26 | 2020-07-02 | Innate Pharma | Leucocyte immunoglobulin-like receptor neutralizing antibodies |
| CA3150428A1 (en) * | 2019-08-12 | 2021-02-18 | Biond Biologics Ltd. | Antibodies against ilt2 and use thereof |
| CN114945594A (zh) * | 2019-12-23 | 2022-08-26 | 株式会社Lg化学 | 抗lilrb1抗体及其用途 |
-
2021
- 2021-07-27 TW TW112122842A patent/TW202340258A/zh unknown
- 2021-07-27 EP EP21851407.3A patent/EP4169950A4/en active Pending
- 2021-07-27 CN CN202180046031.9A patent/CN115867353A/zh active Pending
- 2021-07-27 US US18/003,582 patent/US20230374127A1/en active Pending
- 2021-07-27 MX MX2023001041A patent/MX2023001041A/es unknown
- 2021-07-27 IL IL299942A patent/IL299942A/en unknown
- 2021-07-27 BR BR112022026922A patent/BR112022026922A2/pt unknown
- 2021-07-27 CA CA3186256A patent/CA3186256A1/en active Pending
- 2021-07-27 KR KR1020210098593A patent/KR20220014316A/ko active Search and Examination
- 2021-07-27 WO PCT/KR2021/009696 patent/WO2022025585A1/ko unknown
- 2021-07-27 TW TW110127573A patent/TW202208438A/zh unknown
- 2021-07-27 JP JP2023503488A patent/JP2023537225A/ja active Pending
- 2021-07-27 AU AU2021315366A patent/AU2021315366A1/en active Pending
-
2022
- 2022-12-12 ZA ZA2022/13434A patent/ZA202213434B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4169950A1 (en) | 2023-04-26 |
| ZA202213434B (en) | 2024-04-24 |
| KR20220014316A (ko) | 2022-02-04 |
| EP4169950A4 (en) | 2024-03-20 |
| AU2021315366A9 (en) | 2023-06-29 |
| CN115867353A (zh) | 2023-03-28 |
| AU2021315366A1 (en) | 2023-02-02 |
| TW202340258A (zh) | 2023-10-16 |
| TW202208438A (zh) | 2022-03-01 |
| CA3186256A1 (en) | 2022-02-03 |
| US20230374127A1 (en) | 2023-11-23 |
| WO2022025585A1 (ko) | 2022-02-03 |
| IL299942A (en) | 2023-03-01 |
| JP2023537225A (ja) | 2023-08-31 |
| MX2023001041A (es) | 2023-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021011431A2 (pt) | Anticorpo monoclonal ou um fragmento de anticorpo do mesmo que se liga ao ccr8, seu uso, bem como composição farmacêutica, polinucleotídeo, vetor de expressão e kit | |
| CA3156451A1 (en) | ANTIBODIES WITH SPECIFICITY FOR NECTIN-4 AND THEIR USES | |
| CL2020002305A1 (es) | Uso de anticuerpos sirpa v1 antihumanos y procedimiento de producción de anticuerpos anti-sirpa v1 | |
| BR112018067525A2 (pt) | anticorpos tendo especificidade para o btla e seus usos | |
| BR112019001589A2 (pt) | anticorpos anti-tim-3 | |
| BR112018068340A2 (pt) | imunoglobulinas de ligação ao tgfss1 e usos destas | |
| PE20180480A1 (es) | Anticuerpos de factor xi y metodos de uso | |
| CL2023003068A1 (es) | Compuestos, composiciones y métodos para el tratamiento de trastornos | |
| AR119295A1 (es) | Moléculas de unión a antígeno ligantes de cea | |
| BR112021011684A2 (pt) | Terapia combinada com cd70 e venetoclax, um inibidor de bcl-2, para o tratamento da leucemia mieloide aguda | |
| BR112019010595A2 (pt) | anticorpo ou fragmento de ligação ao antígeno do mesmo, combinação de moléculas de ácido nucleico isoladas, composição farmacêutica, kit, e, método para selecionar um composto. | |
| ZA202206993B (en) | Anti-lilrb1 antibody and uses thereof | |
| BR112021022171A2 (pt) | Anticorpo para tigit, seu uso e método para produzir o mesmo | |
| BR112021009275A2 (pt) | Anticorpo humanizado anti-sirp alfa ou um fragmento de ligação a antígeno do mesmo, composição farmacêutica, molécula de ácido nucleico, e, célula hospedeira. | |
| MX2022000111A (es) | Moleculas de union a claudina-6 y usos de las mismas. | |
| EA202092420A1 (ru) | Антитело против pd-l1 и его применение | |
| BR112022006620A2 (pt) | Anticorpos contra o receptor de poliovírus (pvr) e seus usos | |
| BR112022023117A2 (pt) | Constructos de anticorpos de domínio único neutralizantes de sars-cov2 | |
| EA202191666A1 (ru) | Антитела к il-27 и их применение | |
| CO2021007968A2 (es) | Anticuerpos anti-pmel17 y conjugados de los mismos | |
| BR112022026922A2 (pt) | Anticorpo anti-lilrb1 e usos do mesmo | |
| BR112022003635A2 (pt) | Anticorpo anti-vsig4 ou fragmento de ligação ao antígeno e seu uso | |
| BR112023003366A2 (pt) | Moléculas multiespecíficas de ligação ao antígeno que têm como alvo hiv e métodos de uso | |
| BR112022004302A2 (pt) | Anticorpos anti-il-27 e usos dos mesmos | |
| BR112022007216A2 (pt) | Métodos para tratamento de linfoma difuso, kit e imunoconjugado |